Oncostatin M: a Potential Biomarker to Predict Infection in Patients with Left Ventricular Assist Devices. Issue 8 (10th November 2021)

• Record Type: Journal Article
• Authors: Setiadi, Hendra; El-Banayosy, Ahmed M.; George, Susan; Schmidtke, David W.; El-Banayosy, Aly; Horstmanshof, Douglas A.; Long, James W.
• Is Part Of: ASAIO journal. Volume 68:Issue 8(2022)
• Page Start: 1036
• Page End: 1043
• Publication Date: 2021-11-10
• Subjects: biomarker -- cytokines -- heart failure -- hemocompatibility -- infection -- inflammation -- oncostatin M; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001608
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Infection is a serious adverse event limiting left ventricular assist device (LVAD) therapy in advanced heart failure patients, but a reliable means to identify patients at increased risk of infection is still lacking. We hypothesized that preoperative elevated levels of plasma Oncostatin M (OSM), a cytokine marker of leukocyte activation and inflammation, would be predictive of subsequent infection. We measured plasma OSM in 41 LVAD patients one day before LVAD implantation and postoperatively over two months. Preoperative plasma OSM levels were normal in 27 patients (group A, 4.9 ± 3.2 pg/ml) but elevated in 14 patients (group B, 1649.0 ± 458.9 pg/ml) ( p = 0.003). Early postoperative levels rose in both groups and declined rapidly in group A, with group B declining slowly over two months. Significantly more infections developed in group B than group A patients over two months postimplantation ( p = 0.004). No other routine clinical assessment or laboratory testing afforded this differentiation. These findings suggest that preoperative plasma OSM levels may assist in identifying patients at increased risk of infections after LVAD implantation.